2 Drugmakers Making Sharp Moves

Kite Pharma Inc (KITE) and Raptor Pharmaceutical Corp. (RPTP) both revealed encouraging news this morning

Aug 17, 2015 at 10:33 AM
facebook X logo linkedin

A number of biopharmaceutical firms are making headlines this morning, following upbeat drug news. Specifically, Kite Pharma Inc (NASDAQ:KITE) said its cancer drug, KTE-C19, is on track to start a late-stage trial, and Raptor Pharmaceutical Corp. (NASDAQ:RPTP) received FDA approval to expand its label for Procysbi(R) -- a nephropathic cystinosis treatment -- to include children aged 2-to-6 years.

Of the two, though, only KITE is higher this morning. Specifically, the shares have tacked on 4.6% at $60.65, overcoming broad-market headwinds. The development is a welcome one for investors, who watched the stock get burned last week on poorly received earnings.

One group that may be feeling the heat is short sellers. Almost 15% of Kite Pharma Inc's float is sold short, equivalent to about nine days of trading, at typical volumes. However, the brokerage bunch isn't being caught off-guard, as 100% of analysts have doled out "strong buy" recommendations on the stock.

Meanwhile, after jumping out of the gate and approaching its 80-day moving average, RPTP reversed low, and was last seen down 1.7% at $13.01. Longer term, though, the shares have advanced nearly 24% in 2015, and could find a foothold at their underfoot 100-day trendline -- from which they bounced less than two weeks ago.

Option traders have been extremely bullish toward Raptor Pharmaceutical Corp. in recent weeks. During the last 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 2,077 calls, compared to just six puts.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI